Shenzhen Kangtai Biological Products (300601.SZ) Earnings Analysis

Shenzhen Kangtai Biological Products (300601.SZ) next reports earnings on 2026-08-28, consensus EPS 0.04783 CNY. Last quarter (2026-04-22) it missed with EPS 0.00785 CNY vs 0.06671 CNY est (-88.2%). It has beaten estimates in 0/7 recent quarters (0%). Trailing P/E 175.54.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 300601.SZ next report earnings?

Next earnings date2026-08-28
Consensus EPS estimate0.04783 CNY
Revenue estimate0.76B

300601.SZ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-220.00785 CNY0.06671 CNY-88.2%Miss
2026-04-210.03004 CNY0.05 CNY-39.9%Miss
2025-10-270.01041 CNY0.06671 CNY-84.4%Miss
2025-08-210.01479 CNY0.06243 CNY-76.3%Miss
2025-04-200.02 CNY0.08 CNY-75%Miss
2025-03-310.02 CNYn/an/an/a
2024-10-250.16 CNY0.2 CNY-20%Miss
2024-08-280.1 CNY0.22 CNY-54.5%Miss

Beat rate: 0/7 (0%) over reported quarters with consensus data.

300601.SZ valuation and analyst view

Trailing P/E175.54
Trailing EPS0.07273 CNY
Price / book1.41
Dividend yield0.29%
Market cap13.78B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Shenzhen Kangtai Biological Products (300601.SZ)'s next earnings date?

Shenzhen Kangtai Biological Products is next scheduled to report on 2026-08-28, with a consensus EPS estimate of 0.04783 CNY and revenue estimate of 0.76B.

Did 300601.SZ beat earnings last quarter?

In its 2026-04-22 report, 300601.SZ posted EPS of 0.00785 CNY versus a 0.06671 CNY estimate — a miss of 88.2%.

What is 300601.SZ's earnings track record?

Over the last 7 reported quarters with consensus data, 300601.SZ beat estimates 0 times (0%).

What is 300601.SZ's current P/E ratio and EPS?

300601.SZ trades at a trailing P/E of 175.54 on trailing EPS of 0.07273100414249559 CNY.

What do analysts rate 300601.SZ?

300601.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.